A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke

J. Biller, E. W. Massey, J. R. Marler, H. P. Adam, J. N. Davis, A. Bruno, R. A. Henriksen, R. J. Linhardt, L. B. Goldstein, M. Alberts, C. T. Kisker, G. J. Toffol, C. S. Greenberg, K. J. Banwart, C. Bertels, D. W. Beck, M. Walker, H. N. Magnani

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.

Original languageEnglish
Pages (from-to)262-265
Number of pages4
Issue number2
StatePublished - Feb 1989

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke'. Together they form a unique fingerprint.

Cite this